Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-R rollover study of opnurasib (JDQ443)
ChiCTR2600129840Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opnurasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Clinical safety laboratory tests and Adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600129840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129840.